Screener Summaries Updates Institutions Sign In More Updates › Other Events › EVMN Other Events · Nov 5, 2026
Evommune hosts webcast on EVO570 in-licensing from Hinova Pharmaceuticals EVMN Evommune, Inc.
Evommune announced a pre-recorded webcast to discuss the exclusive licensing of EVO570, an oral VAV1-directed molecular glue degrader, from Hinova Pharmaceuticals. The event covers the drug's biology, preclinical profile, and development plans for rheumatoid arthritis. Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases.
More from Evommune, Inc. Evommune raises $30M in private placement and in-licenses EVO570 for up to $1.1B Nov 4, 2026 Evommune presents EVO301 Phase 2a data showing 55% reduction in atopic dermatitis scores versus 22% for placebo Oct 1, 2026 On September 8, 2026, Evommune announced that its Phase 2b trial of EVO756 for moderate-to-severe atopic dermatitis… Sep 8, 2026 Evommune announced the dosing of the first patient in a Phase 2b clinical trial for EVO756, an oral MRGPRX2 inhibitor… Jul 30, 2026 Evommune, Inc. announced on June 29, 2026, that its Phase 2b trial for EVO756 in treating moderate-to-severe chronic… Jun 29, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
